|
Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits
phosphorylation of downstream proteins involved in BCR-ABL signal transduction.
It has proved beneficial in treating patients with chronic myeloid leukaemia
(CML). In addition, IM demonstrates activity against malignant cells expressing
c-kit and platelet-derived growth factor receptor (PDGF-R). The activity of IM
in the blastic crisis of CML and against various myeloma cell lines suggests
that this drug may also target other cellular components. In the light of the
important role of telomerase in malignant transformation, we evaluated the
effect of IM on telomerase activity (TA) and regulation in various malignant
cell lines. Imatinib mesylate caused a dose-dependent inhibition of TA (up to
90% at a concentration of 15 muM IM) in c-kit-expressing SK-N-MC (Ewing
sarcoma), SK-MEL-28 (melanoma), RPMI 8226 (myeloma), MCF-7 (breast cancer) and
HSC 536/N (Fanconi anaemia) cells as well as in ba/F3 (murine pro-B cells),
which do not express c-kit, BCR-ABL or PDGF-R.
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML Yahoo! Groups Links
|
